Progression through the G 1 phase of the cell cycle is mediated by phosphorylation of the retinoblastoma protein (pRb) resulting in the release of essential transcription factors such as E2F-1. The phosphorylation of pRb is regulated positively by cyclin D 1 /CDK4 and negatively by CDK inhibitors, such as p16 (CDKN2/ MTS-1/INK4A). The p16 /cyclin D 1 /Rb pathway plays a critical role in tumorigenesis and many tumor types display a high frequency of inactivation of at least one component of this pathway. In order to determine the overall contribution of these three components to progression of head and neck squamous cell carcinoma (HNSCC), we examined p16 inactivation, cyclin D 1 ampli®cation, and pRb expression in 23 primary HNSCC tumors and ®ve cell lines. p16 inactivation was detected in 19/23 (83%) primary tumors by detailed genetic analysis and was con®rmed by immunohistochemistry (IHC). Absence of Rb protein expression indicative of pRb inactivation was identi®ed in 2/23 (9%) tumors. In this set of tumors, there was a perfect inverse correlation between p16 and pRb inactivation. Usinḡ uorescence in situ hybridization (FISH) cyclin D 1 ampli®cation was identi®ed in 4/5 (80%) cell lines and 4/11 (36%) primary tumors. However, 2/4 cell lines and all four primary tumors with cyclin D 1 ampli®cation contained a concomitant alteration of p16. Therefore 21/ 23 (91%) of primary HNSCC contained at least one alteration in the p16/cyclin D 1 /Rb pathway. Although p16 and Rb alteration are apparently exclusive, cyclin D 1 ampli®cation occurs concomitantly with the loss of p16 suggesting an additional role for this ampli®cation in HNSCC.
Introduction
The G 1 phase of the cell cycle is controlled by phosphorylation of the retinoblastoma protein (pRb) and mediated in part by cyclin D-cyclin dependent kinase (cdk) 4 complexes. This cdk4 phosphorylation activity is negatively regulated by the tumor suppressor gene p16 (a CDK inhibitor), and positively by cyclin D 1 . Each individual component of this p16-cyclin D 1 -Rb pathway is commonly targeted in various malignancies (Weinberg, 1995; Sherr, 1996) . We previously reported a high frequency (83%) of p16 inactivation in human HNSCC (Reed et al., 1996) and less frequent inactivation (13%) of pRb (Yoo et al., 1994) . Cyclin D 1 ampli®cation has been reported in 22 ± 64% of HNSCC based on several dierent genetic or IHC methods (Jares et al., 1994; Kyomoto et al., 1997; Olshan et al., 1997; Michalides et al., 1995) . However, few reports have simultaneously examined all components of this critical pathway in HNSCC (Olshan et al., 1997; Lukas et al., 1995) .
p16 and pRb inactivation have been reported to be inversely correlated in some tumor types (Shapiro et al., 1995; Parry et al., 1995; Sakaguchi et al., 1996; Andl et al., 1998) . It has thus been assumed that each component of this pathway is an alternative target for abrogation of a common pathway and that alterations of multiple components in the same pathway is not necessary for tumor progression (Serrano et al., 1996) . We thus undertook a comprehensive study of all potential alterations within the p16-cyclin D 1 -Rb pathway in cell lines and primary HNSCC. We found a high frequency of p16 inactivation and cyclin D 1 ampli®cation in cell lines and primary HNSCC. Moreover, a signi®cant proportion of primary tumors contained concomitant alterations of p16 and cyclin D 1 suggesting that unlike p16 and pRb, alterations of these two components are not mutually exclusive.
Results and dscussion p16 status
The p16 gene status in these tumors has been reported previously (Reed et al., 1996) . p16 inactivation was detected by IHC in 19 out of 23 (83%) cases (Table  1) . The IHC results were con®rmed by genetic analysis as previously reported (12 had HD at the p16 locus, ®ve contained methylation of the promoter region of p16, and one had a frameshift mutation in exon 1; Reed et al., 1996) . IHC analysis of p16 appears to be a reliable and practical method to determine p16 inactivation in fresh tissue as reported (Reed et al., 1996) . pRb IHC pRb IHC showed strong nuclear staining in both tumor and normal cells (Figure 1a) . pRb inactivation was observed in two cases out of 23 (9%) exhibiting a good contrast between the negative staining tumor area and the positive staining normal areas (Figure 1b) . The incidence of pRb inactivation was consistent with our previous study on primary HNSCC (Yoo et al., 1994; Andl et al., 1998) .
Cyclin D 1 ampli®cation by FISH FISH was ®rst performed on normal lymphocyte spreads which con®rmed the chromosomal location of the BAC probe on chromosome 11q13 (data not shown). In order to determine the incidence of cyclin D 1 gene ampli®cation, FISH analysis was carried out on both HNSCC cell lines and primary tumors. We identi®ed gene ampli®cation in four out of ®ve (80%) cell lines (Table 1 ). The FaDu cell line contained four control signals and more than 20 cyclin D 1 signals (Figure 1a) . We found two typical appearances of gene ampli®cation in cell lines 011, 012 and 022. Cell line 011 had 4 ± 6 control signals and 10 ± 12 cyclin D 1 signals, and in the metaphase spreads of chromosome 11, it exhibited a homogeneously staining region (HSR, Brodeur and Hogarty, 1998) of the cyclin D 1 gene (Figure 2b ). Cell line 012 and 022 metaphase spreads displayed 4 ± 6 cyclin D 1 signals due to a duplication of the long arm of chromosome 11 seen in each nucleus (Figure 2c ). In the primary tumors, we found four cases of gene ampli®cation out of 11 (36%) cases available (Table 1 ). Figure 2d shows a primary tumor with four control signals and 12 cyclin D 1 signals. Previously, ampli®cation of cyclin D 1 was reported in 22 ± 64% of HNSCC (Jares et al., 1994; Kyomoto et al., 1997; Olshan et al., 1997; Michalides et al., 1995) . These studies used various methods to detect the ampli®cation including Southern blot analysis, Northern blot hybridization, dierential PCR, or IHC. Although the frequency of amplification detected by these various approaches is somewhat 
3 3 2 5 6 3 2 2 a p16 status was assessed by microsatellite analysis, sequencing, and promoter methylation assay (see text; Cairns et al. (1994) (Liggett et al., 1996) consistent, there is the limitation of quantitation by all of these methods. FISH is the most reliable method to analyse gene ampli®cation (Brodeur and Hogarty, 1998 ) because it can demonstrate the minimal region of ampli®cation in situ and can detect the relative gain of gene copy number compared to a control. One cell line (029) in our study had four signals for both chromosome 11 and cyclin D 1 indicative of a simple duplication of the whole chromosome, rather than a true ampli®cation. Furthermore, the appearance of HSRs and apparent duplication, as shown here, provide very strong evidence of gene ampli®cation (Brodeur and Hogarty, 1998) .
Relationship between p16, cyclin D 1 and pRb Table 2 shows the correlation between the p16, pRb and cyclin D 1 status. As reported previously (Shapiro et al., 1995; Parry et al., 1995; Sakaguchi et al., 1996; Andl et al., 1998) , inactivation of p16 and pRB had an inverse correlation which was signi®cant by Fisher's exact test (P=0.0397). In our series, we found concomitant alteration of p16 and cyclin D 1 in four of 11 primary tumors and two of ®ve cell lines.
These results suggest that these two components are not mutually exclusive and can both be altered in a signi®cant proportion of primary tumors. These results must also be interpreted cautiously, however, because of our small sample size. Using more de®nitive methods, our ®ndings are consistent with previous results in cell lines (Lukas et al., 1995) and primary tumors (Olshan et al., 1997) . Strikingly, all but two tumors (21/23, 91%) contained an alteration in either p16 or pRb. This observation con®rms the critical importance of the p16/cyclin D 1 /Rb pathway in the progression of HNSCC.
At least one in vivo study (Lukas et al., 1995) showed that cyclin D 1 ampli®cation and lack of p16 expression cooperatively provided greater growth advantage to the tumor than either of the two abnormalities alone. Recently, two reports (Zwijen et al., 1997; Neuman et al., 1997) showed that cyclin D 1 can bind and activate the estrogen receptor indicative of novel role for cyclin D 1 as a CDK-independent activator of the estrogen receptor. This observation implies a novel function of cyclin D 1 in a critical transcriptional pathway, perhaps involving differentiation responses (Jacks and Weinberg, 1998) .
The most frequent target of inactivation, p16, is lost in most HNSCC and appears critical to the initiation of these neoplasms Mao et al., 1996) . There is evidence to suggest that both pRb and cyclin D 1 ampli®cation occur somewhat later in tumor progression (Yoo et al., 1994; Jares et al., 1994) . Our results suggest that cyclin D 1 ampli®cation may confer an additional advantage to tumor cells in addition to p16/Rb inactivation. This advantage may explain the association of cyclin D 1 ampli®cation with more advanced disease and a poorer outcome (Jares et al., 1994; Kyomoto et al., 1997; Michalides et al., 1995) .
Materials and methods

Cell line and primary tumor samples
Five HNSCC cell lines were derived from patients at the Johns Hopkins Hospital in the Department of Otolaryngology (011, 012, 022, and 029) or obtained from the American Type Culture Collection (FaDu). These cell lines were cultured and harvested as previously described (Liggett et al., 1996) . The p16 and pRb status of these cell lines were de®ned previously (Lukas et al., 1995; Liggett et al., 1996) . Twenty-three randomly selected primary HNSCC tumors were collected following surgical resection with prior consent from the Johns Hopkins Hospital patients. DNA from tumor samples and blood as a normal control were extracted as described .
IHC
IHC for p16 was processed on fresh frozen sections as described (Reed et al., 1996) using a monoclonal antibody, DCS-50 (Lab Vision, Fremont, CA, USA). pRb was stained immunohistochemically on archival formalin-®xed and paran-embedded tissue using a monoclonal antibody, G 3-245 (PharMingen, San Diego, CA, USA) at 1 : 100 ± 200 (Sakaguchi et al., 1996; Geradts et al., 1994) . Brie¯y, 5 mm sections were cut from blocks and deparanized. After blocking, slides were treated and microwaved in Citra (BioGenex, San Ramon, CA, USA) for 20 min. Slides were incubated with normal serum followed by the primary antibody for 2 h at room temperature and washed in PBS. Immunohistochemical staining was performed with the use of the Vectastain Elite ABC kit (Burlongame, CA, USA), 3,3'-diaminobenzidine tetrahydrochloride development, and counterstained with methylgreen. pRb expression was considered normal if de®nite nuclear staining could be identi®ed in all areas of the tumor. Aberrant expression was de®ned if the tumor area showed no nuclear staining and if de®nite nuclear staining was seen in immediately adjacent nonneoplastic cells.
Genetic analysis
Homozygous deletion (HD) of p16 was detected by detailed microsatellite analysis (Reed et al., 1996) . The criteria for loss of heterozygosity (LOH) and HD was described previously (Reed et al., 1996; Cairns et al., 1995; Okami et al., 1997) . The methylation status of the 5' CpG island in p16 was determined by Southern blot analysis Cairns et al., 1997) and sequence analysis of exons 1 and 2 of p16 was carried out as described (Cairns et al., 1994) .
FISH
A genomic DNA probe for FISH analysis was obtained by screening a genomic library, Down to the Well system (GenomeSystems, St. Louis, MO, USA), with primers for the 3' untranslated region of the cyclin D 1 gene (sense, 5'-GGAAAGCTTCATTCTCCTTGTTG-3', anti-sense, 5'-TCTAGGTAAACCTCTGAGGTCC-3'). The BAC (bacterial arti®cial chromosome) clone #10842 containing both the 5' and 3' ends of the gene was labeled with digoxigenein-11-dUTP (Boehringer Manheim, Indianapolis, IN, USA) by nick translation. The FISH procedure used on cell line preparations and frozen sections was described previously Cairns et al., 1995; Lichter and Cremer, 1992) . A biotinlabeled chromosome 11 a satellite probe (Oncor, Gaithersburg MD, USA) was co-hybridized with the cyclin D 1 probe, and both probes were detected using the in situ hybridization kit (Oncor, Gaithersburg MD, USA) according to the manufacturer's instruction. Signals from at least 100 nuclei were counted under a¯uorescence microscope equipped with a triple-pass ®lter. In normal epithelia or lymphocytes, the percentage of nuclei with two signals of cyclin D 1 was 52 ± 67%. Three or more signals were observed in only 5 ± 6% of the nuclei in normal areas, suggesting a low incidence of non-speci®c hybridization for this probe. On the basis of the evaluation of normal non malignant areas, we set the criteria for determination of cyclin D 1 gene ampli®cation as follows. If a nucleus contained; (a) more than three signals of both cyclin D 1 and chromosome 11; and (b) if the ratio of cyclin D 1 /chromosome 11 was over 1.1, the nucleus was considered to have cyclin D 1 ampli®cation. Furthermore, if the percentage of the nuclei with amplification exceeded 20%, the sample was interpreted as having cyclin D 1 ampli®cation (Jenkins et al., 1997; Simpson et al., 1997) . For documentation, images were captured by a CCD camera (Photometrics, Tucson, AZ, USA) and processed using the Oncor Image analyzing system (Oncor).
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